Cardinal Health becomes Catalent, launches officially

Published: 21-Jun-2007

Catalent Pharma Solutions, formerly Cardinal Health Pharmaceutical Technologies and Services, today announced its official launch as an independent operating company. The Blackstone Group acquired the business from Cardinal Health in April 2007.


Catalent Pharma Solutions, formerly Cardinal Health Pharmaceutical Technologies and Services, today announced its official launch as an independent operating company. The Blackstone Group acquired the business from Cardinal Health in April 2007.

Catalent is a provider of advanced technologies, as well as development, manufacturing and packaging solutions for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. The firm says that it holds more than 1,000 patents and patent applications.

Catalent commercialised softgel capsule technology and Liqui-Gel formulations, created the 'fast dissolve' oral tablet category with Zydis, and introduced the vegetable-based capsule VegiCaps Soft.

Catalent's technologies are used in a number of well-known consumer health and prescription drug products.

'Catalent intimately understands the global challenges our customers face while developing and commercialising life-enhancing and life-saving drugs or innovative consumer health products,' said John Lowry, company president and ceo.

The Catalent name was created to combine the ideas embodied by the words 'catalyst' and 'talent'.

  • Companies:
  • Catalent
See more

You may also like

Manufacturing

Ardena acquires Catalent's US oral dose manufacturing facility, adding further bioanalytical services

Read more
The CRO/CDMO will now integrate its advanced late-stage and small-scale commercial oral drug product manufacturing services with an extended list of bioanalytical services, enhancing its offering to clients in the North American region

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Ardena acquires Catalent's US oral dose manufacturing facility, adding further bioanalytical services

The CRO/CDMO will now integrate its advanced late-stage and small-scale commercial oral drug product manufacturing services with an extended list of bioanalytical services, enhancing its offering to clients in the North American region
Finance

Novo Holdings completes acquisition of Catalent

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
Manufacturing

Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation

Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its large-scale spray drying unit (GEA PSD-4) at its Boston (MA, US) facility

Improvements to the oral medicine formulation development process

Aston University have teamed up with Catalent to determine faster ways to identify the best ingredients for optimal medicine formulations
Research & Development

CPHI Barcelona Snapshot: Catalent

Influenced by the rising desire of biotechs to develop novel treatments, drug modalities entering the market are changing
Manufacturing

Catalent expands integrated development, manufacturing and supply for modalities

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service
Manufacturing

Catalent adds cryogenic capabilities to support gene development

The facility in Shiga will include the storage, kitting, and distribution of advanced therapies at ultra-low temperatures for clinical trials
Subscribe now